Pneumococcal disease describes a group of illnesses caused by the bacterium Streptococcus pneumoniae, also known as pneumococcus. This bacterial pathogen, which affects both children and adults, is a major cause of death and illness worldwide. In fact, according to the World Health Organization (WHO), pneumococcal disease is the number one vaccine-preventable cause of death in children younger than 5 years of age worldwide.
As antibiotic use grows in lower-income countries so does antibiotic resistance, says report.
In a major public health success, the introduction of pneumococcal conjugate vaccine PCV13, or Prevnar 13, in 2010 in the United States is associated with reduction in socioeconomic disparities and the near elimination of Black-white-based racial disparities for invasive pneumococcal disease.
In nearly half a million American homes, washing hands to prevent COVID-19 isn't as simple as soaping up and singing "Happy Birthday" twice while scrubbing.
New research has uncovered the risk factors for Fijians carrying a pneumonia-causing bacteria.
A new study published in the journal Archives of Diseases of Childhood in March 2020 reveals that despite a drop to less than half, compared to 25 years ago, infection is still a cause of significant mortality among children. The most common cause of infection-related deaths in this age group are respiratory infections.
Vaccines can be far more targeted and effective than they are today. A new method will allow us to develop new vaccines more cheaply and efficiently and perhaps get one step ahead of bacteria.
Blue Water Vaccines Inc., a biopharmaceutical company focused on creating transformative vaccines solving global health challenges, has entered into an exclusive worldwide license agreement for the development of a Streptococcus Pneumoniae vaccine with St. Jude Children's Research Hospital, the nation's leading hospital dedicated to understanding, treating and curing childhood cancer and other life-threatening diseases.
Pneumococcal conjugate vaccine have been highly effective in reducing pneumonia and other invasive infections caused by Streptococcus pneumoniae bacteria.
New research has found that rates of disease caused by the bacterium Streptococcus pneumoniae could be substantially reduced by changing our approach to vaccination.
Air pollution is a long-standing global problem, which is responsible for 7 million deaths each year, with 7 percent of these attributed to pneumonia. A new study highlights how air pollution affects the airways making the body susceptible to developing the pneumococcal disease.
The National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, today announced the establishment of the Infectious Diseases Clinical Research Consortium, a clinical trials network that will encompass the Institute's long-standing Vaccine and Treatment Evaluation Units (VTEUs) and create a new consortium leadership group
There have been repeated reports of outbreaks of “vaccine-preventable disease” or VPDs across United States over the past few years. A new research letter was published this week in the JAMA Pediatrics. It was titled, “Association of Vaccine-Preventable Disease Incidence With Proposed State Vaccine Exemption Legislation.”
Researchers have uncovered a crucial link between dietary zinc intake and protection against Streptococcus pneumoniae, the primary bacterial cause of pneumonia.
Researchers have mapped the most common bacterial cause of pneumonia around the world and revealed how these bacteria evolve in response to vaccination.
A vaccine against Streptococcus pneumoniae, a major cause of childhood illness and mortality in the developing world, sharply reduced the incidence of serious pneumococcal disease among children in a large Kenyan community after it was introduced in 2011, according to a new study from researchers at the Johns Hopkins Bloomberg School of Public Health.
If mitigating racial disparities in those who contract pneumococcal diseases, such as meningitis and pneumonia, is a top public health priority, then recommending that all adults get a pneumococcal vaccine at age 50 would likely be effective guidance, according to a University of Pittsburgh School of Medicine analysis published today in the journal Vaccine.
Pfizer Inc. announced today that its 20-Valent Pneumococcal Conjugate Vaccine candidate, PF-06482077, received Breakthrough Therapy designation from the US Food and Drug Administration for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in the vaccine in adults aged 18 years and older. Pfizer expects to start Phase 3 trials in a few months.
Pneumococcus is an important cause of pneumonia, sepsis and meningitis. This bacterium commonly resides in the nasal cavity.
In 2004, pneumonia killed more than 2 million children worldwide, according to the World Health Organization. By 2015, the number was less than 1 million.
Pfizer Inc., in partnership with Parents magazine, announced today the results of a national survey of more than 2,000 new and expectant parents assessing their knowledge of childhood infectious diseases, such as measles, whooping cough and invasive pneumococcal disease, and the measures parents can take to help prevent them.